1. Home
  2. DGICA vs TECX Comparison

DGICA vs TECX Comparison

Compare DGICA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DGICA

Donegal Group Inc.

HOLD

Current Price

$18.69

Market Cap

714.2M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$20.68

Market Cap

618.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGICA
TECX
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
714.2M
618.9M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
DGICA
TECX
Price
$18.69
$20.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$21.00
★ $71.00
AVG Volume (30 Days)
93.8K
★ 226.8K
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 4.12%
N/A
EPS Growth
N/A
★ 40.70
EPS
★ N/A
N/A
Revenue
★ $978,014,322.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.82
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$16.11
$15.60
52 Week High
$21.06
$39.53

Technical Indicators

Market Signals
Indicator
DGICA
TECX
Relative Strength Index (RSI) 52.15 28.34
Support Level $18.42 $20.52
Resistance Level $19.54 $23.61
Average True Range (ATR) 0.37 1.10
MACD 0.07 0.07
Stochastic Oscillator 76.65 9.50

Price Performance

Historical Comparison
DGICA
TECX

About DGICA Donegal Group Inc.

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: